Advertisement
Organisation › Details
Schrödinger Inc. (Nasdaq: SDGR)
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages its software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs. Founded in 1990, Schrödinger has over 400 employees and is engaged with customers and collaborators in more than 70 countries. *
Start | 1990-01-01 established | |
Group | Schrödinger (Group) | |
Industry | software | |
Industry 2 | AI-based drug discovery / AI-based drug development | |
Person | Farid, Ramy (Schrödinger 202011 CEO) | |
Region | New York, NY | |
Country | United States (USA) | |
Street | 120 West 45th Street 17th Floor | |
City | 10036-4041 New York, NY | |
Tel | +1-212-295-5800 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | D: 101 to 500 (2020-11-23) |
* Document for »About Section«: Schrödinger, Inc.. (11/23/20). "Press Release: Schrödinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb". New York, NY. | ||
Record changed: 2024-06-20 |
Advertisement
More documents for Schrödinger (Group)
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top